January 3, 2019
Results ‘encouraging’ from phase II trial for relapsed acute myeloid leukemia
UNC Lineberger’s Joshua Zeidner, MD, reported preliminary data at the 60th American Society of Hematology Annual Meeting from a phase II clinical trial for administering a high-dose of the chemotherapy treatment cytarabine followed by an immune checkpoint inhibitor, pembrolizumab, in patients with acute myeloid leukemia that had relapsed or no longer responded to other treatment.